免疫检查点抑制剂在肺癌治疗中的研究进展  

Research progress of immune checkpoint inhibitors in the treatment of lung cancer

作　　者：马骏[1] 张红颖 吴艾平[1] 高广毅[2] Ma Jun;Zhang Hongying;Wu Aiping;Gao Guangyi(Department of Oncology,Huai′an Traditional Chinese Medicine Hospital Affiliated to Nanjing University of Chinese Medicine,Huai′an 223001,China;Department of Oncology,Huai′an Second People′s Hospital of Jiangsu Province,Huai′an 223001,China)

机构地区：[1]南京中医药大学附属淮安中医院肿瘤科,淮安223001 [2]江苏省淮安市第二人民医院肿瘤科,223001

出　　处：《国际肿瘤学杂志》2021年第11期683-687,共5页Journal of International Oncology

基　　金：江苏省中医药科技发展计划(YB201967)。

摘　　要：近年来,免疫检查点抑制剂在肺癌的治疗中是一个里程碑式的突破。免疫检查点种类较多,包括程序性死亡蛋白-1(PD-1)、程序性死亡蛋白配体-1(PD-L1)、细胞毒性T淋巴细胞抗原4(CTLA-4)、杀伤细胞免疫球蛋白样受体(KIR)、T细胞免疫球蛋白和ITIM结构域蛋白(TIGIT)、细胞免疫球蛋白和黏蛋白3(TIM-3)等,与免疫治疗的疗效及耐药密切相关。PD-1/PD-L1抑制剂已被中国国家药品监督管理局及美国食品药品监督管理局批准用于肺癌的一线治疗,可延长患者的总生存期及无进展生存期。CTLA-4抑制剂或TIGIT抑制剂联合PD-1/PD-L1抑制剂的双免疫治疗亦取得良好疗效,但可能发生更严重的不良事件。KIR及TIM-3靶点与免疫治疗的耐药性密切相关。In recent years,immune checkpoint inhibitors are a milestone in the treatment of lung cancer.There are many kinds of immune checkpoints,which are closely related to the efficacy and drug resis-tance of immunotherapy,including programmed death-1(PD-1),programmed death ligand-1(PD-L1),cytotoxic T-lymphocyte antigen 4(CTLA-4),killer cell immunoglobulin-like receptor(KIR),T cell immunoglobulin and ITIM domain(TIGIT),T-cell immunoglobulin and mucin domain-containing protein 3(TIM-3),etc.PD-1/PD-L1 inhibitors have been approved by China National Medical Products Administration and U.S.Food and Drug Administration for the first-line treatment of lung cancer,which can improve overall survival and progression-free survival of patients.The double immunotherapies of CTLA-4 inhibitors or TIGIT inhibitors combined with PD-1/PD-L1 inhibitors also achieve good results,however,more serious adverse events may occur.The KIR and TIM-3 targets are closely related to the drug resistance of immunotherapy.

关 键 词：免疫疗法 肺肿瘤 免疫检查点抑制剂 

分 类 号：R734.2[医药卫生—肿瘤]